stockrow
Friday 6 November 2026
Export VCEL’s income statement to Excel — free account
Vericel Corporation
VCEL Healthcare Biotechnology
Vericel Corporation’s revenue for fiscal 2025 (year ended December 2025) was $276.3 million, up 16.5% from fiscal 2024.
- Revenue
- +26.5%
- EPS
- +180.0%
- Free cash flow
- −19.4%
Quarter to September 2026, against a year earlier
54.47
2.69
+5.20%
Follow VCEL
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
7 | 8 | 8 | 8 |
| 5.11% | 6.59% | 7.16% | 9.44% | ||
| 3.59% | 4.72% | 5.16% | 6.86% | ||
ROIC |
3.18% | 4.67% | 5.49% | 7.88% | |
Return on Tangible Assets |
5.39% | 7.06% | 7.62% | 10.06% | |
Average Days of Receivables |
111.82 | 90.45 | 90.22 | 92.10 | |
Free Cash Flow per Share |
0.49 | 0.94 | 1.21 | 1.13 | |
Free Cash Flow |
24.75 | 47.49 | 61.66 | 57.89 | |
Capital Expenditures |
(27.16) | (14.21) | (8.01) | (7.42) | |
| Other line items | |||||
Cash ROIC |
5.03% | 9.47% | 11.58% | 10.44% | |
Accounts Receivable Turnover |
3.78 | 4.66 | 4.38 | 4.56 | |
Accounts Payable Turnover |
3.56 | 4.11 | 4.66 | 4.69 | |
Inventory Turnover |
4.05 | 4.15 | 4.43 | 4.70 | |
Average Days of Payables |
81.76 | 94.41 | 96.56 | 88.02 | |
Days of Inventory on Hand |
90.71 | 91.14 | 86.10 | 75.22 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
9.98% | 9.73% | 9.52% | 9.17% | |
Selling, General and Administrative Expense of Revenue |
60.45% | 59.71% | 59.08% | 56.98% | |
Share Based Compensation of Revenue |
14.03% | 13.20% | 12.24% | 11.30% | |
Interest Coverage |
17.53 | 24.76 | 28.49 | 42.01 | |
Operating CF/Net income |
3.14 | 2.87 | 2.88 | 1.96 | |
Depreciation/Fixed assets |
0.11 | 0.11 | 0.12 | 0.00 | |
Capex/Depreciation |
(2.35) | (1.16) | (0.61) | 0.00 | |
Revenue per Share |
5.49 | 5.75 | 6.00 | 6.33 | |
Operating CF per Share |
1.03 | 1.22 | 1.36 | 1.28 | |
Capex per Share |
(0.54) | (0.28) | (0.16) | (0.14) | |
Capex to Sales |
0.10 | 0.05 | 0.03 | 0.02 |
Columns are period end dates · fundamentals updated 5 Nov 2026